Broad Clinical Laboratories, LLC

Broad Clinical Laboratories, LLC, a non-profit subsidiary of the Broad Institute of MIT and Harvard headquartered in Cambridge, Massachusetts, delivers clinical whole genome sequencing and specialized genetic testing services to federal healthcare agencies as a prime contractor, with no subcontract footprint and no set-aside designations across all awards.

The vendor's customer base concentrates heavily on the Department of Veterans Affairs Veterans Health Administration. Five of seven awards (combined potential value $1.9 million) flow to VA Veterans Integrated Service Network 1, which covers northern New England medical facilities. The remaining two awards (combined potential value $204 thousand) come from the National Institute of Allergy and Infectious Diseases under the NIH. This concentration — 90% of awards and 91% of combined potential value to VA — reflects Broad Clinical Laboratories' specialization in supporting veteran healthcare diagnostics and medical research.

Broad Clinical Laboratories holds a single-award Indefinite Delivery Contract with VA Veterans Health Administration, valued at $1.14 million with performance through February 6, 2029, from which three delivery orders have been issued totaling $635 thousand in combined potential value. Recent representative work includes a $210 thousand firm fixed-price delivery order issued July 8, 2026, for genetic testing services to VA medical facilities in northern New England; a $185 thousand delivery order awarded February 7, 2024, for genetic testing to support healthcare delivery and medical research for veterans; and a $58 thousand 150-test clinical whole genome sequencing purchase order from the National Institute of Allergy and Infectious Diseases under the FY26 UDO Initiative, completed April 29, 2026.

Activity remains light but steady. The source captures one award in 2020, one in 2023, three in 2024, one in 2025, and one in 2026 — each award represents individual delivery orders or purchase orders rather than contract wins. Combined obligated dollars across all awards total $983 thousand against $2.1 million in combined potential value, indicating a 46% invoiced-to-ceiling ratio. No recompete cliff appears in the next twenty-four months; the underlying VA IDC extends through February 2029. Broad Clinical Laboratories operates as a wholly owned subsidiary with no named parent-subsidiary teaming or multi-vendor consortium relationships in the source data, positioning it as a specialized clinical genomics provider embedded in the broader Broad Institute federal research ecosystem rather than a scaled federal contractor.